{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T18:13:00Z","timestamp":1763748780293,"version":"3.40.5"},"reference-count":76,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s353411","type":"journal-article","created":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:40:20Z","timestamp":1668444020000},"page":"3159-3174","source":"Crossref","is-referenced-by-count":6,"title":["Role of Rucaparib in the Treatment of Prostate Cancer: Clinical Perspectives and Considerations"],"prefix":"10.2147","volume":"Volume 14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2283-4893","authenticated-orcid":true,"given":"Maximillian S","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5777-2138","authenticated-orcid":true,"given":"Hanan","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,11]]},"reference":[{"key":"ref1","unstructured":"Cancer (IARC) TIA for R on. Global cancer observatory. Available from: https:\/\/gco.iarc.fr\/. Accessed June 20, 2022."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref3","unstructured":"SEER. Cancer of the prostate - cancer stat facts. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html. Accessed June10, 2022."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1038\/emboj.2011.158","volume":"30","author":"Massie","year":"2011","journal-title":"EMBO J"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1159\/000519861","volume":"100","author":"Achard","year":"2022","journal-title":"Oncology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/iju.13512","volume":"25","author":"Komura","year":"2018","journal-title":"Int J Urol off J Jpn Urol Assoc"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/pros.24340","volume":"82","author":"Khan","year":"2022","journal-title":"Prostate"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMoa1603144","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","volume":"161","author":"Dan","year":"2015","journal-title":"Cell"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1200\/JCO.18.00358","volume":"37","author":"Castro","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"Wang","year":"2018","journal-title":"Genes Dev"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.1002\/pros.24353","volume":"82","author":"Cotter","year":"2022","journal-title":"Prostate"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41416-020-01114-x","volume":"124","author":"Lozano","year":"2021","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","volume":"30","author":"de Bono","year":"2019","journal-title":"Annals Oncol"},{"volume-title":"Prostate Cancer: Cellular and Genetic Mechanisms of Disease Development and Progression","year":"2019","key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-32656-2_5"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nsmb.2096","volume":"18","author":"Holloman","year":"2011","journal-title":"Nat Struct Mol Biol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"Choi","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/cancers12030564","volume":"12","author":"Curtin","year":"2020","journal-title":"Cancers"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"ref23","unstructured":"Drugs.com. Niraparib - brand name list from Drugs.com. Available from: https:\/\/www.drugs.com\/ingredient\/niraparib.html. Accessed July 14, 2022."},{"key":"ref24","unstructured":"Drugs.com. Talazoparib - brand name list from Drugs.com. Available from: https:\/\/www.drugs.com\/ingredient\/talazoparib.html. Accessed July 14, 2022."},{"key":"ref25","unstructured":"Drugs.com. Olaparib - brand name list from Drugs.com. Available from: https:\/\/www.drugs.com\/ingredient\/olaparib.html. Accessed July 7, 2022."},{"key":"ref26","unstructured":"Drugs.com. Rucaparib - brand name list from Drugs.com. Available from: https:\/\/www.drugs.com\/ingredient\/rucaparib.html. Accessed July 7, 2022."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.3390\/ijms22084203","volume":"22","author":"Valabrega","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref28","unstructured":"Clovis Oncology, Inc. TRITON2: a multicenter, open-label phase 2 study of rucaparib in patients with metastatic castration-resistant prostate cancer associated with homologous recombination deficiency. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02952534. Accessed June 30, 2022."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/onco.13585","volume":"26","author":"Anscher","year":"2021","journal-title":"Oncologist"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1200\/JCO.20.01035","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"key":"ref31","first-page":"1121","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"ref32","unstructured":"NCI Dictionary of Cancer Terms \u2013 NCI. Definition of median survival; 2011. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/median-survival. Accessed July 6, 2022."},{"key":"ref33","unstructured":"Clovis Oncology, Inc. TRITON3: a multicenter, randomized, open label phase 3 study of rucaparib versus physician\u2019s choice of therapy for patients with metastatic castration resistant prostate cancer associated with homologous recombination deficiency. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02975934. Accessed July 17, 2022."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"TPS389","DOI":"10.1200\/JCO.2018.36.6_suppl.TPS389","volume":"36","author":"Ryan","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref35","unstructured":"Drugs.com. Rucaparib dosage guide + max dose, adjustments. Available from: https:\/\/www.drugs.com\/dosage\/rucaparib.html. Accessed July 7, 2022."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2147\/CMAR.S335962","volume":"14","author":"Labadie","year":"2022","journal-title":"Cancer Manag Res"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"10781552221094308","DOI":"10.1177\/10781552221094308","author":"Keisner","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00280-022-04413-7","volume":"89","author":"Green","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref39","unstructured":"National Cancer Institute (US). Common Terminology Criteria for Adverse Events (CTCAE); 2017:155."},{"key":"ref40","unstructured":"ClinicalTrials.gov. Results data element definitions for interventional and observational studies. Available from: https:\/\/prsinfo.clinicaltrials.gov\/results_definitions.html#AdverseEventsDefinition. Accessed July 11, 2022."},{"key":"ref41","unstructured":"Rucaparib. LiverTox: clinical and research information on drug-induced liver injury. National Institute of Diabetes and Digestive and Kidney Diseases; 2012. Available from: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548767\/. Accessed July 11, 2022."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11523-020-00715-z","volume":"15","author":"Lorusso","year":"2020","journal-title":"Target Oncol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00280-021-04278-2","volume":"88","author":"Grechko","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref44","unstructured":"EMA. Rubraca. European medicines agency; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rubraca. Accessed July 12, 2022."},{"key":"ref45","unstructured":"EMA. Lynparza. European medicines agency; 2018. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lynparza. Accessed July 12, 2022."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"907","DOI":"10.3390\/cancers14040907","volume":"14","author":"Marchetti","year":"2022","journal-title":"Cancers"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jcm11061734","volume":"11","author":"Teyssonneau","year":"2022","journal-title":"J Clin Med"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3390\/cancers14040953","volume":"14","author":"Martorana","year":"2022","journal-title":"Cancers"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/00498254.2017.1346332","volume":"48","author":"McCormick","year":"2018","journal-title":"Xenobiotica"},{"key":"ref52","unstructured":"LYNPARZA- olaparib tablet, film coated. Package insert. AstraZeneca Pharmaceuticals LP; 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa. Accessed July 13, 2022."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1080\/00498254.2020.1737759","volume":"50","author":"Liao","year":"2020","journal-title":"Xenobiotica"},{"key":"ref54","unstructured":"RUBRACA- rucaparib tablet, film coated. Package insert. Clovis Oncology, Inc; 2022. Available from: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=a6d46c03-bb1d-417b-b8e5-3bffe352fe29. Accessed July 13, 2022."},{"key":"ref55","unstructured":"Janssen Research & Development, LLC. A phase 2 efficacy and safety study of niraparib in men with metastatic castration-resistant prostate cancer and DNA-repair anomalies. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02854436. Accessed July 13, 2022."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"853211","DOI":"10.3389\/fonc.2022.853211","volume":"12","author":"Wei","year":"2022","journal-title":"Front Oncol"},{"key":"ref58","unstructured":"Pfizer. TALAPRO-1: a phase 2, open-label, response rate study of talazoparib in men with DNA repair defects and metastatic castration-resistant prostate cancer who previously received taxane-based chemotherapy and progressed on at least 1 novel hormonal agent (enzalutamide and\/or abiraterone acetate\/prednisone). clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03148795. Accessed July 14, 2022."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1093\/oncolo\/oyac172","volume":"27","author":"Mehra","year":"2022","journal-title":"Oncologist"},{"key":"ref61","unstructured":"ClinicalTrials.gov. Home. Available from: https:\/\/clinicaltrials.gov\/ct2\/home. Accessed July 18, 2022."},{"key":"ref62","unstructured":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase II trial of rucaparib in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH). clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03413995. Accessed July 18, 2022."},{"key":"ref63","unstructured":"University of Utah. A phase II study of rucaparib monotherapy in nonmetastatic, hormone-sensitive prostate cancer demonstrating \u201cBRCAness\u201d genotype (ROAR). clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03533946. Accessed July 21, 2022."},{"key":"ref64","unstructured":"Clovis Oncology, Inc. A phase 2 multicenter, open-label study of rucaparib as treatment for solid tumors associated with deleterious mutations in homologous recombination repair genes. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04171700. Accessed July 21, 2022."},{"key":"ref65","unstructured":"Clovis Oncology, Inc. A phase 1b, open-label, parallel arm study to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral rucaparib in combination with other anticancer agents in patients with metastatic castration resistant prostate cancer. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04179396. Accessed July 28, 2022."},{"key":"ref66","unstructured":"Alliance for Clinical Trials in Oncology. CASPAR - A phase III trial of enzalutamide and rucaparib as a novel therapy in first-line metastatic castration-resistant prostate cancer. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04455750. Accessed July 28, 2022."},{"key":"ref67","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1200\/JCO.2022.40.6_suppl.128","volume":"40","author":"Carneiro","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.ygyno.2016.07.092","volume":"142","author":"Wang","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ejca.2021.09.043","volume":"160","author":"Fizazi","year":"2022","journal-title":"Eur J Cancer"},{"key":"ref71","unstructured":"Incyte Corporation. A phase 1\/2, open-label, dose-escalation\/dose-expansion, safety and tolerability study of INCB057643 in subjects with advanced malignancies. clinicaltrials.gov; 2022. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02711137. Accessed July 21, 2022."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/1078-0432.CCR-18-4071","volume":"26","author":"Falchook","year":"2020","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"Li","year":"2020","journal-title":"Mol Cancer"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"Kim","year":"2020","journal-title":"Nat Commun"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=85407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=85407","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,14]],"date-time":"2022-11-14T16:40:30Z","timestamp":1668444030000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/role-of-rucaparib-in-the-treatment-of-prostate-cancer-clinical-perspec-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":76,"URL":"https:\/\/doi.org\/10.2147\/cmar.s353411","relation":{},"ISSN":["1179-1322"],"issn-type":[{"type":"electronic","value":"1179-1322"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}